Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis

NCT00379600 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00379600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00379600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
December 31, 2006
Enrollment
96 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid